KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Share-based Compensation: 2011-2025

Historic Share-based Compensation for TherapeuticsMD (TXMD) over the last 14 years, with Jun 2025 value amounting to $1,000.

  • TherapeuticsMD's Share-based Compensation fell 98.96% to $1,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $81,000, marking a year-over-year decrease of 85.46%. This contributed to the annual value of $264,000 for FY2024, which is 79.23% down from last year.
  • According to the latest figures from Q2 2025, TherapeuticsMD's Share-based Compensation is $1,000, which was down 95.65% from $23,000 recorded in Q1 2025.
  • TherapeuticsMD's Share-based Compensation's 5-year high stood at $7.3 million during Q3 2021, with a 5-year trough of $1,000 in Q2 2025.
  • For the 3-year period, TherapeuticsMD's Share-based Compensation averaged around $155,900, with its median value being $103,500 (2024).
  • As far as peak fluctuations go, TherapeuticsMD's Share-based Compensation soared by 142.27% in 2021, and later plummeted by 98.96% in 2025.
  • TherapeuticsMD's Share-based Compensation (Quarterly) stood at $5.3 million in 2021, then tumbled by 43.42% to $3.0 million in 2022, then tumbled by 96.15% to $116,000 in 2023, then tumbled by 79.31% to $24,000 in 2024, then crashed by 98.96% to $1,000 in 2025.
  • Its last three reported values are $1,000 in Q2 2025, $23,000 for Q1 2025, and $24,000 during Q4 2024.